Cytek Biosciences Stock Options
| CTKB Stock | USD 5.68 0.22 4.03% |
Cytek Biosciences' latest option contracts expiring on April 17th 2025 are carrying combined implied volatility of 1.79 with a put-to-call open interest ratio of 7.5 over 8 outstanding agreements suggesting investors are buying way more puts than calls on contracts expiring on April 17th 2025.
Open Interest Against April 17th 2025 Option Contracts
2025-04-17
The chart above shows Cytek Biosciences' distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. Cytek Biosciences' open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for Cytek Biosciences' option, there is no secondary market available for investors to trade.
In The Money vs. Out of Money Option Contracts on Cytek Biosciences
Analyzing Cytek Biosciences' in-the-money options over time can help investors to take a profitable long position in Cytek Biosciences regardless of its overall volatility. This is especially true when Cytek Biosciences' options are deep in the money. These options can be identified using deltas that are over 0.75. Deep in-the-money Cytek Biosciences' options could be used as guardians of the underlying stock as they move almost dollar for dollar with Cytek Biosciences' stock while costing only a fraction of its price.
Cytek Biosciences' stock options are financial instruments that give investors the right to buy or sell shares of Cytek Biosciences common stock at a specified price for a given time period. Generally speaking, an option to purchase or sell Cytek stock makes it part of the underlying stock when the option's price is tied to the movement of the underlying stock. If Cytek Biosciences' stock price goes up or down, the stock options follow.
At present, Cytek Biosciences' Other Stockholder Equity is projected to increase significantly based on the last few years of reporting. The current year's Stock Based Compensation is expected to grow to about 26.6 M, whereas Total Stockholder Equity is forecasted to decline to about 256.8 M. Cytek Biosciences In The Money Call Balance
When Cytek Biosciences' strike price is surpassing the current stock price, the option contract against Cytek Biosciences stock is said to be in the money. When it comes to buying Cytek Biosciences' options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on Cytek Biosciences are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.
Cytek Current Options Market Mood
Cytek Biosciences' open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps Cytek Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.
Put-to-Call Open Interest
Put-to-Call Volume
Unfortunately, most Cytek Biosciences' options investors are not very successful. Cytek Biosciences' option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.
Rule 16 of the current Cytek contract
Base on the Rule 16, the options market is currently suggesting that Cytek Biosciences will have an average daily up or down price movement of about 0.11% per day over the life of the 2025-04-17 option contract. With Cytek Biosciences trading at USD 5.68, that is roughly USD 0.006355. If you think that the market is fully incorporating Cytek Biosciences' daily price movement you should consider buying Cytek Biosciences options at the current volatility level of 1.79%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Cytek |
Purchasing Cytek Biosciences options can give investors a meaningful hedge against losses and, therefore, could be used conservatively to decrease the volatility of your portfolio. However, many options could also amount to little more than gambling, significantly enhancing your overall portfolio risk. One simple example of these aggressive strategies is the sale of "uncovered" Cytek calls. Remember, the seller must deliver Cytek Biosciences stock to the call owner when a call is exercised.
Cytek Biosciences Option Chain
When Cytek Biosciences' strike price is surpassing the current stock price, the option contract against Cytek Biosciences stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
Cytek Biosciences' option chain is a display of a range of information that helps investors for ways to trade options on Cytek. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for Cytek. It also shows strike prices and maturity days for a Cytek Biosciences against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone. | Open Int | Strike Price | Current Spread | Last Price | |||
Call | CTKB250417C00002500 | 0 | 2.5 | 0.6 - 5.5 | 0.6 | In |
Call | CTKB250417C00005000 | 0 | 5.0 | 0.35 - 4.8 | 0.35 | In |
Call | CTKB250417C00007500 | 8 | 7.5 | 0.05 - 4.5 | 0.35 | Out |
Call | CTKB250417C00010000 | 0 | 10.0 | 0.0 - 0.75 | 0.75 | |
Put | CTKB250417P00002500 | 10 | 2.5 | 0.0 - 0.75 | 0.6 | Out |
Put | CTKB250417P00005000 | 50 | 5.0 | 0.0 - 2.9 | 0.45 | Out |
Put | CTKB250417P00007500 | 0 | 7.5 | 0.9 - 5.0 | 0.9 | In |
Put | CTKB250417P00010000 | 0 | 10.0 | 3.8 - 7.0 | 3.8 | In |
Cytek Biosciences Selling And Marketing Expenses Over Time
Selling And Marketing Expenses |
| Timeline |
Cytek Total Stockholder Equity
Total Stockholder Equity |
|
Cytek Biosciences Corporate Management
| Todd Garland | Chief Officer | Profile | |
| Ming Yan | CTO Director | Profile | |
| Melik Ulusu | Senior Chain | Profile | |
| Mark Edinger | VP Affairs | Profile | |
| Allen Poirson | Senior Development | Profile | |
| Connie Wedel | Chief Officer | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytek Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry. For information on how to trade Cytek Stock refer to our How to Trade Cytek Stock guide.You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytek Biosciences. If investors know Cytek will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytek Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.658 | Earnings Share (0.08) | Revenue Per Share | Quarterly Revenue Growth 0.073 | Return On Assets |
The market value of Cytek Biosciences is measured differently than its book value, which is the value of Cytek that is recorded on the company's balance sheet. Investors also form their own opinion of Cytek Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Cytek Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytek Biosciences' market value can be influenced by many factors that don't directly affect Cytek Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytek Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytek Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytek Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.